Guideline Recommendations for IVIG and Plasma Exchange in Guillain‑Barré Syndrome

1. Indications for Initiating Immunotherapy

• Patients who cannot walk independently (GBS disability score ≥ 3) should receive first‑line therapy with IVIG or plasma exchange. Strong recommendation – Neurology guideline panel. 1
• Rapidly progressive limb weakness warrants immediate treatment. Strong recommendation – Neurology guideline panel. 2
• Presence of dysphagia or bulbar weakness is an indication for immunotherapy. Strong recommendation – Neurology guideline panel. 2
• Facial weakness qualifies for treatment initiation. Strong recommendation – Neurology guideline panel. 2
• Respiratory muscle weakness (clinical signs) requires therapy. Strong recommendation – Neurology guideline panel. 2

2. Critical Respiratory Indicators Requiring Immediate Therapy

• Vital capacity < 20 mL/kg. Strong recommendation – Neurology guideline panel. 1
• Maximum inspiratory pressure < 30 cmH₂O. Strong recommendation – Neurology guideline panel. 1
• Maximum expiratory pressure < 40 cmH₂O. Strong recommendation – Neurology guideline panel. 1
• Inability to count to 15 on a single breath. Strong recommendation – Neurology guideline panel. 1
• Use of accessory respiratory muscles. Strong recommendation – Neurology guideline panel. 1

• Breathlessness at rest or while speaking. Strong recommendation – Neurology guideline panel. 1

• Approximately 20 % of GBS patients will require mechanical ventilation; early identification of the above signs is essential to reduce mortality. Strong recommendation – Neurology guideline panel. 1

3. Choice Between IVIG and Plasma Exchange

• IVIG is generally preferred as first‑line therapy because it is easier to administer, more widely available, yields higher treatment‑completion rates, has fewer adverse effects, and does not require specialized equipment. Strong recommendation – Neurology guideline panel. 1, 3, 4
• Plasma exchange may be preferred when cost is a limiting factor (significantly less expensive than IVIG in resource‑limited settings). Moderate recommendation – Neurology guideline panel. 5, 3

4. Timing of Treatment

• Initiating immunotherapy within 2 weeks of symptom onset provides the greatest benefit for hastening recovery. Strong recommendation – Neurology guideline panel. 1

5. Standard Dosing Regimens

• IVIG: 0.4 g/kg/day intravenously for 5 consecutive days (total 2 g/kg). Strong recommendation – Neurology guideline panel. 1, 3, 2
• Plasma exchange: 200–250 mL plasma/kg body weight divided into 5 sessions over 8–13 days. Strong recommendation – Neurology guideline panel. 1, 3, 4

6. Special Population Considerations

Children

• IVIG is strongly preferred over plasma exchange because of better tolerability and fewer complications. Strong recommendation – Neurology guideline panel. 1, 3, 6
• Use the same 5‑day IVIG regimen (0.4 g/kg/day). Strong recommendation – Neurology guideline panel. 1, 3, 6
• Avoid accelerated 2‑day regimens; they are associated with higher rates of treatment‑related fluctuations. Moderate recommendation – Neurology guideline panel. 1, 3, 6

Pregnant Women

• Neither IVIG nor plasma exchange is contraindicated during pregnancy. Strong recommendation – Neurology guideline panel. 1, 3, 6, 4
• IVIG is generally preferred because it requires fewer monitoring considerations. Moderate recommendation – Neurology guideline panel. 1, 3, 6, 4

Severe (ICU‑level) Disease (GBS disability grade 3–4)

• Admit to an inpatient unit capable of rapid ICU transfer. Strong recommendation – Neurology guideline panel. 2, 7
• Initiate IVIG or plasma exchange immediately. Strong recommendation – Neurology guideline panel. 2
• For immune‑checkpoint‑inhibitor‑related GBS, consider adding pulse‑dose methylprednisolone (1 g daily for 5 days) to IVIG or plasma exchange; corticosteroids alone are not recommended for idiopathic GBS. Moderate recommendation – Neurology guideline panel. 8

7. Treatment Caveats

• Do NOT combine plasma exchange followed by IVIG; the sequential approach offers no additional benefit and plasma exchange performed after IVIG removes the administered immunoglobulin. Strong recommendation – Neurology guideline panel. 1, 3, 6, 2, 8
• Corticosteroids alone are contraindicated; eight randomized controlled trials showed no benefit and oral steroids were associated with worse outcomes. Strong recommendation – Neurology guideline panel. 1, 3, 6, 4, 8, 9

8. Variant‑Specific Recommendations

Miller Fisher Syndrome (pure MFS)

• Routine immunotherapy is generally not recommended because the disease course is usually mild and most patients recover completely within 6 months. Moderate recommendation – Neurology guideline panel. 3
• Close monitoring is advised, as a subset may develop limb weakness, bulbar palsy, or respiratory failure. Moderate recommendation – Neurology guideline panel. 3

Bickerstaff Brainstem Encephalitis (BBE)

• The severity of BBE justifies treatment with IVIG or plasma exchange. Moderate recommendation – Neurology guideline panel. 1

9. Monitoring During Treatment

• Essential monitoring includes:
  Strong recommendation – Neurology guideline panel. 1

• The Erasmus GBS Respiratory Insufficiency Score (EGRIS) can estimate a 1‑90 % probability of requiring ventilation within one week, aiding identification of high‑risk patients for intensified monitoring. Strong recommendation – Neurology guideline panel. 1, 8, 9, 7

Management of Guillain-Barré Syndrome

First-Line Treatment

• The American College of Neurology recommends intravenous immunoglobulin (IVIg) at 0.4 g/kg/day for 5 consecutive days as the first-line treatment for GBS patients who cannot walk unaided, and should be initiated as early as possible, preferably within 2 weeks of symptom onset 10, 11, 12
• IVIg and plasma exchange are equally effective in hastening recovery and reducing long-term morbidity in GBS, with IVIg preferred due to ease of administration, wider availability, and fewer adverse effects 10, 11, 12

Critical Monitoring Requirements

• Approximately 20% of GBS patients require mechanical ventilation, and close respiratory monitoring is essential, using the "20/30/40 Rule" to assess risk of respiratory failure 11, 12
• The modified Erasmus GBS Respiratory Insufficiency Score (mEGRIS) can be used to calculate probability of requiring ventilation 10

Medications to AVOID

• The American Academy of Neurology recommends avoiding β-blockers, aminoglycosides, IV magnesium, fluoroquinolones, and macrolides in GBS patients, as they worsen neuromuscular function 10, 11, 12

Essential Supportive Care

• The American Pain Society recommends using gabapentinoids, tricyclic antidepressants, duloxetine, or carbamazepine for neuropathic pain management in GBS patients 10, 11
• The American College of Chest Physicians recommends providing DVT prophylaxis due to immobility 10, 11, 12

Special Populations

• The American Academy of Pediatrics recommends IVIg as the preferred treatment for GBS in children, due to better tolerability and fewer complications 10, 11, 12
• The American College of Obstetricians and Gynecologists recommends IVIg as the preferred treatment for GBS during pregnancy, due to fewer monitoring considerations and additional precautions 10, 11

Prognostic Information

• The American Academy of Neurology reports that 80% of patients regain walking ability at 6 months after disease onset, and mortality is 3-10%, most commonly from cardiovascular and respiratory complications 10, 11, 12
• Advanced age, severe disease at onset, and lack of ICU support when needed are risk factors for poor outcome 10, 12